Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus RESPORAL.
CEFTRIAXONE IN PLASTIC CONTAINER vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
2 mg orally twice daily
None Documented
None Documented
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic